WO2002024158A8 - Pulmonary delivery in treating disorders of the central nervous system - Google Patents

Pulmonary delivery in treating disorders of the central nervous system

Info

Publication number
WO2002024158A8
WO2002024158A8 PCT/US2001/029311 US0129311W WO0224158A8 WO 2002024158 A8 WO2002024158 A8 WO 2002024158A8 US 0129311 W US0129311 W US 0129311W WO 0224158 A8 WO0224158 A8 WO 0224158A8
Authority
WO
WIPO (PCT)
Prior art keywords
central nervous
nervous system
drug
particles
pulmonary delivery
Prior art date
Application number
PCT/US2001/029311
Other languages
French (fr)
Other versions
WO2002024158A2 (en
WO2002024158A3 (en
Inventor
Raymond T Bartus
Dwaine E Emerich
Original Assignee
Advanced Inhalation Res Inc
Raymond T Bartus
Dwaine E Emerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/665,252 external-priority patent/US6514482B1/en
Priority to ES01971210.8T priority Critical patent/ES2621549T3/en
Priority to CA2421974A priority patent/CA2421974C/en
Priority to AU2001291122A priority patent/AU2001291122B2/en
Priority to AU9112201A priority patent/AU9112201A/en
Priority to EP01971210.8A priority patent/EP1318785B1/en
Application filed by Advanced Inhalation Res Inc, Raymond T Bartus, Dwaine E Emerich filed Critical Advanced Inhalation Res Inc
Priority to DK01971210.8T priority patent/DK1318785T3/en
Priority to JP2002528195A priority patent/JP5421510B2/en
Publication of WO2002024158A2 publication Critical patent/WO2002024158A2/en
Publication of WO2002024158A3 publication Critical patent/WO2002024158A3/en
Publication of WO2002024158A8 publication Critical patent/WO2002024158A8/en
Priority to CY20171100358T priority patent/CY1118851T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration.
PCT/US2001/029311 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system WO2002024158A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2002528195A JP5421510B2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in the treatment of disorders of the central nervous system
CA2421974A CA2421974C (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system
AU2001291122A AU2001291122B2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system
AU9112201A AU9112201A (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system
EP01971210.8A EP1318785B1 (en) 2000-09-19 2001-09-19 Pulmonary delivery of l-dopa
ES01971210.8T ES2621549T3 (en) 2000-09-19 2001-09-19 L-Dopa pulmonary administration
DK01971210.8T DK1318785T3 (en) 2000-09-19 2001-09-19 PULMONAL ADMINISTRATION OF L-DOPA
CY20171100358T CY1118851T1 (en) 2000-09-19 2017-03-21 Pulmonary administration of L-DOPA

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/665,252 2000-09-19
US09/665,252 US6514482B1 (en) 2000-09-19 2000-09-19 Pulmonary delivery in treating disorders of the central nervous system
US09/877,734 2001-06-08
US09/877,734 US6613308B2 (en) 2000-09-19 2001-06-08 Pulmonary delivery in treating disorders of the central nervous system

Publications (3)

Publication Number Publication Date
WO2002024158A2 WO2002024158A2 (en) 2002-03-28
WO2002024158A3 WO2002024158A3 (en) 2002-09-19
WO2002024158A8 true WO2002024158A8 (en) 2003-02-20

Family

ID=27099159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029311 WO2002024158A2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system

Country Status (10)

Country Link
US (7) US6613308B2 (en)
EP (2) EP3061453A1 (en)
JP (2) JP5421510B2 (en)
AU (2) AU9112201A (en)
CA (1) CA2421974C (en)
CY (1) CY1118851T1 (en)
DK (1) DK1318785T3 (en)
ES (1) ES2621549T3 (en)
PT (1) PT1318785T (en)
WO (1) WO2002024158A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US7779020B2 (en) * 2002-03-01 2010-08-17 International Business Machines Corporation Small-footprint applicative query interpreter method, system and program product
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
FR2812545B1 (en) * 2000-08-03 2003-03-28 Air Liquide Sante Int INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
DE60230035D1 (en) * 2001-05-24 2009-01-08 Alexza Pharmaceuticals Inc ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM OR TRIAZOLAM BY INHALATION
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
WO2002094237A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
AU2002310074B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of migraine through an inhalation route
WO2002094234A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of opioids through an inhalation route
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
WO2002094232A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
DE60228703D1 (en) * 2001-05-24 2008-10-16 Alexza Pharmaceuticals Inc ADMINISTRATION OF SEDATIVA HYPNOTICS BY INHALATION
WO2002094233A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antiemetics through an inhalation route
WO2002094246A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20030032638A1 (en) * 2001-05-24 2003-02-13 Kim John J. Delivery of benzodiazepines through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
DE10137633A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Treatment or prophylaxis of attention deficit hyperactivity disorder, using the dopamine agonist pramexipol or its salt
EP1446102A1 (en) 2001-11-21 2004-08-18 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
SI1458360T1 (en) 2001-12-19 2011-08-31 Novartis Ag Pulmonary delivery of aminoglycosides
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
WO2003079991A2 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Method for administration of growth hormone via pulmonary delivery
ES2389156T3 (en) * 2002-03-20 2012-10-23 Civitas Therapeutics, Inc. Lung administration of levodopa
EP1496880A4 (en) * 2002-04-24 2007-12-12 Res Dev Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
CA2483687A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
EP1523318A4 (en) * 2002-06-24 2007-07-04 Res Dev Foundation Treatment of human multiple myeloma by curcumin
LT1531794T (en) * 2002-06-28 2017-08-25 Civitas Therapeutics, Inc. Inhalable epinephrine
WO2004006841A2 (en) * 2002-07-12 2004-01-22 University Of Rochester Use of amino acids for treatment of various conditions
ATE420647T1 (en) * 2002-11-26 2009-01-15 Alexza Pharmaceuticals Inc USE OF LOXAPINE FOR THE PRODUCTION OF A PAIN TREATMENT AGENT
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
MXPA05005609A (en) * 2002-11-26 2005-07-26 Alexza Pharmaceuticals Inc Treatment of headache with antipsychotics delivered by inhalation.
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
WO2004071491A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
AU2004231342A1 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
EP1635762B1 (en) * 2003-06-13 2021-03-03 Civitas Therapeutics, Inc. Low dose pharmaceutical powders for inhalation
JP2007503475A (en) 2003-08-26 2007-02-22 リサーチ ディベロップメント ファウンデーション Osteoclast formation inhibitor and method of use thereof
CA2536738A1 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
ES2399279T3 (en) 2004-06-18 2013-03-27 Novartis Ag Tobramycin formulations for the treatment of endobronchial infections
ES2385934T3 (en) 2004-08-20 2012-08-03 Mannkind Corporation CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA.
KR101644250B1 (en) 2004-08-23 2016-07-29 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
AU2005290238A1 (en) 2004-09-18 2006-04-06 Department Of Veterans Affairs Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
CA2580606A1 (en) 2004-09-18 2006-03-30 University Of Maryland, Baltimore Therapeutic agents targeting the ncca-atp channel and methods of use thereof
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
JP5749881B2 (en) 2005-04-22 2015-07-15 ユニヴェルシテ デ ジュネーブ Polylactide composition and use thereof
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9511075B2 (en) 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
WO2008097835A2 (en) 2007-02-02 2008-08-14 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
EP2114160B1 (en) 2007-02-09 2016-11-16 University of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
PL2425820T3 (en) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
EP2173380A4 (en) * 2007-07-13 2011-08-31 Abbott Biotech Ltd METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
SI2328601T1 (en) * 2008-08-15 2020-08-31 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
JP2012502915A (en) 2008-09-15 2012-02-02 バイオビスタ インコーポレイテッド Compositions and methods for treating epilepsy
EP2719380A3 (en) 2008-09-16 2014-07-30 University of Maryland, Baltimore SUR1 inhibitors for therapy
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5667095B2 (en) 2009-03-11 2015-02-12 マンカインド コーポレイション Apparatus, system and method for measuring inhaler resistance
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
RU2577698C2 (en) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Dry powder formulations and methods of treating pulmonary diseases
WO2010124276A2 (en) 2009-04-24 2010-10-28 Vanderbilt Universtiy Anti-tgf-beta induction of bone cell function and bone growth
CA2764505C (en) 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP3100610A1 (en) 2009-07-24 2016-12-07 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
JP2013501071A (en) * 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ， インコーポレイテッド Formulations containing linaclotide
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
PL2536742T3 (en) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
JP5921545B2 (en) 2010-08-11 2016-05-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド Stable formulation of linaclotide
EP2606152B1 (en) 2010-08-18 2016-10-05 Fred Hutchinson Cancer Research Center Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9399053B2 (en) 2011-07-22 2016-07-26 The University Of Chicago Treatments for migraine and related disorders
PL2776055T3 (en) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9655905B2 (en) 2011-09-14 2017-05-23 King Abdullah University Of Science And Technology Treatment of sickle cell disease
WO2013041969A2 (en) 2011-09-21 2013-03-28 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
RU2019104004A (en) 2012-01-23 2019-03-07 Сейдж Терапьютикс, Инк. MEDICINAL FORMS OF NEUROACTIVE STEROIDS AND METHODS OF TREATING CNS DISORDERS
EP2852413A4 (en) 2012-02-16 2016-04-27 Univ Toledo Xenoantigen-displaying anti-cancer vaccines and method of making
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
CN107596518B (en) 2012-02-29 2021-04-23 普马特里克斯营业公司 Inhalable dry powder
AR092821A1 (en) 2012-04-20 2015-05-06 Sucampo Ag CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE
AU2013266232B2 (en) 2012-05-23 2017-08-03 The Ohio State University Lipid nanoparticle compositions for antisense oligonucleotides delivery
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
WO2014066206A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics , Inc. Reducing inter-patient variability of levodopa plasma concentrations
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
BR112015010601B1 (en) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
EP4335505A2 (en) 2012-11-30 2024-03-13 The Regents of The University of California Anticonvulsant activity of steroids
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
FR3000392B1 (en) * 2012-12-27 2015-03-27 Virbac NOVEL VETERINARY PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THEIR PREPARATION
WO2014160339A1 (en) 2013-03-13 2014-10-02 Board Of Regents, The University Of Texas System Compounds for treating inflammatory and hyperproliferative diseases
ES2754388T3 (en) 2013-03-15 2020-04-17 Mannkind Corp Compositions and methods of microcrystalline dicetopiperazine
SG11201507981TA (en) * 2013-03-26 2015-10-29 Optinose As Nasal administration
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
EP2981247B1 (en) 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
JP2016518388A (en) 2013-04-30 2016-06-23 オティトピック インク． Dry powder formulation and usage
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
CN105899528B (en) 2013-12-02 2020-09-01 贝勒医学院 Identification of novel polypeptide hormones for maintaining optimal body weight and blood glucose
CN106102748A (en) * 2014-02-20 2016-11-09 奥迪托皮克股份有限公司 For the dry powder formulations sucked
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US9693994B2 (en) 2014-04-09 2017-07-04 Research Development Foundation Class IIa HDAC inhibitors for the treatment of infection
EP3831375A1 (en) * 2014-04-21 2021-06-09 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
WO2016025202A1 (en) 2014-08-14 2016-02-18 The Regents Of The University Of Colorado Antibody-sirna conjugates and uses therefor
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN107106641B (en) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 Powder formulation
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
WO2016172026A1 (en) 2015-04-20 2016-10-27 The Board Of Regents Of The University Of Texas System Clec11a is a bone growth agent
US20160317503A1 (en) * 2015-05-01 2016-11-03 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
US10962551B2 (en) 2015-06-17 2021-03-30 The Johns Hopkins University TDP-43 in degenerative disease
CA2991108A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth
US11040025B2 (en) 2016-02-17 2021-06-22 The Johns Hopkins University Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
WO2017147370A1 (en) 2016-02-24 2017-08-31 The Johns Hopkins University Novel antiviral proteins and their uses in therapeutic methods
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
RU2022102537A (en) 2016-03-08 2022-03-30 Сейдж Терапьютикс, Инк. NEUROACTIVE STEROIDS, THEIR COMPOSITIONS AND APPLICATIONS
AU2017230792B2 (en) 2016-03-10 2023-08-10 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
KR20230038214A (en) 2016-03-17 2023-03-17 더 존스 홉킨스 유니버시티 Methods for preventing or treating parkinson's disease by the farnesylation of paris
WO2017173055A1 (en) 2016-03-30 2017-10-05 The Johns Hopkins University Olfr90 specificity and methods of detection
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
WO2017210658A1 (en) * 2016-06-03 2017-12-07 Otitopic Inc. Dry powder formulations for inhalation
US11149275B2 (en) 2016-10-10 2021-10-19 The Johns Hopkins University Device and method to treat esophageal disorders
MX2019006745A (en) 2016-12-09 2019-10-14 Alexza Pharmaceuticals Inc Method of treating epilepsy.
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
MX2020002769A (en) 2017-09-22 2020-07-20 Otitopic Inc Dry powder compositions with magnesium stearate.
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP3710029A4 (en) 2017-11-16 2021-08-18 University of Maine System Board of Trustees Compositions and methods for modulating endothelial cell migration and angiogenesis
WO2019118527A1 (en) 2017-12-14 2019-06-20 The Johns Hopkins University Novel anti-fungal inhibitors
EP3921029A4 (en) 2019-02-07 2022-12-07 Baylor College of Medicine Periosteal skeletal stem cells in bone repair
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
JPS6122019A (en) 1984-07-06 1986-01-30 Tomio Konno Inhalation cell active chemical and method for using same
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
WO1986006959A1 (en) 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
EP0259383B1 (en) * 1986-03-10 1991-01-23 Kurt Dr. Burghart Pharmaceutical preparation and process for preparing the same
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5166202A (en) 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
GB9101592D0 (en) 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
ATE179605T1 (en) * 1991-02-09 1999-05-15 B S D Bio Science Dev Snc Di O ANTIREACTIVE ANTIASTHMATIC EFFECT OF ACETYL SALICYLIC ACID BY INHALATION
ATE204262T1 (en) 1991-09-18 2001-09-15 Glaxo Group Ltd BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS
US5457100A (en) 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
KR100419037B1 (en) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 Methods of delivery of insulin through the lungs and their composition
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
CA2152684A1 (en) 1994-07-01 1996-01-02 Richard Anthony Henry Aerosol delivery of midazolam
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6103270A (en) 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
EP0954282B1 (en) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5958902A (en) 1997-04-16 1999-09-28 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DK1180020T4 (en) 1999-05-27 2009-10-05 Acusphere Inc Porous drug matrices and processes for their preparation
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
WO2002094243A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same

Also Published As

Publication number Publication date
JP5421510B2 (en) 2014-02-19
JP2004509141A (en) 2004-03-25
ES2621549T3 (en) 2017-07-04
US20030235537A1 (en) 2003-12-25
CA2421974A1 (en) 2002-03-28
US6979437B2 (en) 2005-12-27
US20090162441A1 (en) 2009-06-25
EP1318785A2 (en) 2003-06-18
DK1318785T3 (en) 2017-04-03
US20040265242A1 (en) 2004-12-30
US20140193501A1 (en) 2014-07-10
CY1118851T1 (en) 2018-01-10
US20040228923A1 (en) 2004-11-18
EP1318785B1 (en) 2016-12-21
US20120087952A1 (en) 2012-04-12
WO2002024158A2 (en) 2002-03-28
US6613308B2 (en) 2003-09-02
AU9112201A (en) 2002-04-02
CA2421974C (en) 2011-03-29
AU2001291122B2 (en) 2005-03-10
JP2012180378A (en) 2012-09-20
US20020058009A1 (en) 2002-05-16
EP3061453A1 (en) 2016-08-31
PT1318785T (en) 2017-04-19
WO2002024158A3 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO2002024158A3 (en) Pulmonary delivery in treating disorders of the central nervous system
HUP0102892A2 (en) Drug delivery system comprising a tightly compacted solid medicament stock, process for its preparation and for its use
EP3104854B1 (en) Mast cell stabilizers for lung disease treatment
WO2003080022A3 (en) Analgesics for nasal administration
WO2017011729A1 (en) Combination therapies for the treatment of lung diseases
AU3400501A (en) Improvements in or relating to the delivery of oral drugs
CA2304975A1 (en) Stabilized preparations for use in metered dose inhalers
WO2001074247A3 (en) Method for measuring changes in the airways of humans and other mammals
KR930701992A (en) How to get rid of mucus secretions that remain in the lungs of patients
US7431916B2 (en) Administration of medicinal dry powders
US5679714A (en) Administration of ketamine for detoxification and treatment of tobacco addiction
CA2152684A1 (en) Aerosol delivery of midazolam
EP0814790B1 (en) Administration of ketamine for detoxification
Van Renterghem et al. Intravenous versus nebulized terbutaline in patients with acute severe asthma; a double-blind randomized study
CZ287114B6 (en) Therapeutic preparation in the form of aerosol and use of gas mixture
Crompton Nebulized or intravenous beta 2 adrenoceptor agonist therapy in acute asthma?
CA2265198A1 (en) Method of producing a nicotine medicament and a medicament made by the method
Verbeek et al. Treatment of asthma-related respiratory arrest with endotracheal abuterol (Salbutamol)
Hasani et al. Paediatric premedication: A comparison of sublingual buprenorphine and midazolam in children (4-10 years) scheduled for adenotonsillectomy
Lahdensuo Bronchodilator effects of fenoterol and salbutamol administered by intermittent positive pressure breathing to patients with asthma or chronic obstructive bronchitis
CN117899164A (en) Novel aerosolized dosage form system and its use in the preparation of a medicament
Fairbanks Cocaine: Friend or foe?
CN113925849A (en) Dry powder inhalation preparation of expectorant and preparation method thereof
Pauwels Inhalation device, pulmonary deposition and clinical effects of inhaled therapy
JP2002161030A (en) Method for inhaling mixed powder having different particle diameter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 2001291122

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2421974

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002528195

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2001971210

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001971210

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001971210

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001291122

Country of ref document: AU